Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
46 hedge funds and large institutions have $31.5M invested in Argos Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 3 closing their positions.
533% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $169K
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
13% more capital invested
Capital invested by funds: $27.8M → $31.5M (+$3.67M)
7% more funds holding
Funds holding: 43 → 46 (+3)
4.32% more ownership
Funds ownership: 11.04% → 15.36% (+4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$4.39M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 3 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$661K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$594K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$582K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$353K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$163K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
-$85.7K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$75.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$29.4K |
ARGS Hedge Fund Activity: Q3 2016 in Review
46 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q3 2016, worth a combined $31.5M — up 13% from $27.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARGS positions and 3 closed out — a net gain of 3 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $4.39M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $353K sold.
- 46 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q3 2016, up from 43 in Q2 2016.
- Funds reported $31.5M of Argos Therapeutics, Inc. stock for Q3 2016, up 13% quarter-over-quarter.
- 6 funds opened new Argos Therapeutics, Inc. positions in Q3 2016 and 3 closed out, a net change of +3 holders.
- The largest Argos Therapeutics, Inc. buyer in Q3 2016 was Wasatch Advisors, an estimated $4.39M added.
- The largest Argos Therapeutics, Inc. seller in Q3 2016 was Oxford Asset Management, an estimated $353K sold.
Based on aggregated 13F filings for Q3 2016.